Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $54.00 Average PT from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued a report on the stock in the last year is $50.00.

A number of research analysts recently weighed in on ARCT shares. Scotiabank reissued an “outperform” rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Wall Street Zen raised shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Wells Fargo & Company dropped their price target on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an “overweight” rating on the stock in a research report on Tuesday. Citigroup reissued a “buy” rating and set a $49.00 price target (up from $47.00) on shares of Arcturus Therapeutics in a research report on Tuesday. Finally, Canaccord Genuity Group dropped their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th.

Arcturus Therapeutics Trading Up 29.0%

Arcturus Therapeutics stock opened at $19.21 on Thursday. Arcturus Therapeutics has a 1-year low of $8.04 and a 1-year high of $25.88. The firm has a market capitalization of $521.74 million, a price-to-earnings ratio of -8.61 and a beta of 2.26. The firm’s fifty day moving average price is $13.29 and its two-hundred day moving average price is $13.30.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.77. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. The firm had revenue of $28.30 million for the quarter, compared to analyst estimates of $17.64 million. On average, research analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current year.

Institutional Trading of Arcturus Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC increased its holdings in Arcturus Therapeutics by 3.9% during the first quarter. ARK Investment Management LLC now owns 2,008,480 shares of the biotechnology company’s stock worth $21,270,000 after buying an additional 74,629 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Arcturus Therapeutics by 3.8% in the first quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company’s stock worth $18,521,000 after purchasing an additional 64,367 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its stake in shares of Arcturus Therapeutics by 129.7% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company’s stock worth $14,409,000 after purchasing an additional 479,482 shares in the last quarter. Woodline Partners LP increased its stake in shares of Arcturus Therapeutics by 3.5% in the fourth quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company’s stock worth $13,693,000 after purchasing an additional 26,956 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Arcturus Therapeutics by 6.4% in the second quarter. Geode Capital Management LLC now owns 606,291 shares of the biotechnology company’s stock worth $7,889,000 after purchasing an additional 36,671 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.